Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Caroline Lohrisch"'
Autor:
Elena Zaikova, Brian Y. C. Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Tamara Shenkier, Christine Simmons, Sara Taylor, Diego Villa, Ruth Miller, Rosalia Aguirre-Hernandez, Samuel Aparicio, Karen Gelmon
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Circulating tumour DNA (ctDNA) detection via liquid biopsy is an emerging alternative to tissue biopsy, but its potential in treatment response monitoring and prognosis in triple negative breast cancer (TNBC) is not yet well understood. Here
Externí odkaz:
https://doaj.org/article/8d2ce9df04da4b8887485568500718ae
Autor:
Emily B Jackson, Lovedeep Gondara, Caroline Speers, Rekha Diocee, Alan M Nichol, Caroline Lohrisch, Karen A Gelmon
Publikováno v:
Breast, Vol 70, Iss , Pp 25-31 (2023)
Prior data about the influence of age at diagnosis of breast cancer on patient outcomes and survival has been conflicting. Using the Breast Cancer Outcomes Unit database at BC Cancer, this retrospective population-based study identified a cohort of 2
Externí odkaz:
https://doaj.org/article/cd717b8b345d40088e2863f95c41fbb7
Autor:
Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J. D. Ross, Bruce C. Carleton
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining th
Externí odkaz:
https://doaj.org/article/9165ac2f07534bafac3874bed40e322d
Autor:
Stephen K. Chia, Susan L. Ellard, Mihaela Mates, Stephen Welch, Catalin Mihalcioiu, Wilson H. Miller, Karen Gelmon, Caroline Lohrisch, Vikaash Kumar, Sara Taylor, Linda Hagerman, Rachel Goodwin, Tao Wang, Shingo Sakashita, Ming S. Tsao, Elizabeth Eisenhauer, Penelope Bradbury
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-8 (2017)
Abstract Background The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foret
Externí odkaz:
https://doaj.org/article/339a000fc2ce4f629f2c9ae8021f9690
Autor:
Elizaveta Vasilyeva, Alan Nichol, Brendan Bakos, Anise Barton, Michelle Goecke, Elaine Lam, Erin Martin, Caroline Lohrisch, Elaine McKevitt
Publikováno v:
The American Journal of Surgery.
Publikováno v:
American Society of Clinical Oncology Educational Book. :60-72
Endocrine therapy has undergone major changes in the past few years, and is no longer a “one-size-fits-all” prescription. This article discussed some of the new developments and directions.
Autor:
Maryam, Dosani, Sarah Nicole, Hamilton, Lovedeep, Gondara, Caroline, Speers, Rekha Manhas, Diocee, Alan, Nichol, Caroline, Lohrisch, Pauline, Truong
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:805-815
Locoregional recurrence risk and the role of locoregional radiation therapy (LRRT) in pN0(i+) and pN1mi breast cancer are unclear. This study compares locoregional relapse-free survival (LRRFS) in patients with pN0(i+) and pN1mi relative to pN0 and p
Autor:
Steven J.M. Jones, Marco A. Marra, Janessa Laskin, Aly Karsan, Ian Bosdet, Sean Young, Kasmintan A. Schrader, Sophie Sun, Daniel Renouf, Howard Lim, Karen Gelmon, Stephen Yip, Stephen Chia, Caroline Lohrisch, Tamara Shenkier, Diego Villa, Sheridan Wilson, Wendie Den Brok, Richard A. Moore, Yongjun Zhao, Andrew J. Mungall, Jacqueline E. Schein, Yussanne Ma, Nina Thiessen, Karen L. Mungall, Richard Corbett, Peter Eirew, Caralyn Reisle, Carolyn Ch'ng, Pinaki Bose, Martin Jones, Sreeja Leelakumari, Katayoon Kasaian, Erin Pleasance, Yaoqing Shen, Eric Y. Zhao
Supplementary Figures S1-S5. Supplementary Tables S1-S5. Figure S1. Comparison of SNV mutation signatures across histological and molecular subtypes. Figure S2. Treatment timelines and radiographic outcomes. Figure S3. Mutation signature stability me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4586fc5b4e370296a583398c3906b1c2
https://doi.org/10.1158/1078-0432.22462229.v1
https://doi.org/10.1158/1078-0432.22462229.v1
Autor:
Steven J.M. Jones, Marco A. Marra, Janessa Laskin, Aly Karsan, Ian Bosdet, Sean Young, Kasmintan A. Schrader, Sophie Sun, Daniel Renouf, Howard Lim, Karen Gelmon, Stephen Yip, Stephen Chia, Caroline Lohrisch, Tamara Shenkier, Diego Villa, Sheridan Wilson, Wendie Den Brok, Richard A. Moore, Yongjun Zhao, Andrew J. Mungall, Jacqueline E. Schein, Yussanne Ma, Nina Thiessen, Karen L. Mungall, Richard Corbett, Peter Eirew, Caralyn Reisle, Carolyn Ch'ng, Pinaki Bose, Martin Jones, Sreeja Leelakumari, Katayoon Kasaian, Erin Pleasance, Yaoqing Shen, Eric Y. Zhao
Table S5: Data from this study have been submitted to the European Genome-Phenome Archive (EGA) (www.ebi.ac.uk/ega/home) under the study accession number EGAS00001001159. This table provides the accession numbers for each dataset included in this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d796107e53bf5da9ff4675c9b50a97
https://doi.org/10.1158/1078-0432.22462226
https://doi.org/10.1158/1078-0432.22462226
Autor:
Steven J.M. Jones, Marco A. Marra, Janessa Laskin, Aly Karsan, Ian Bosdet, Sean Young, Kasmintan A. Schrader, Sophie Sun, Daniel Renouf, Howard Lim, Karen Gelmon, Stephen Yip, Stephen Chia, Caroline Lohrisch, Tamara Shenkier, Diego Villa, Sheridan Wilson, Wendie Den Brok, Richard A. Moore, Yongjun Zhao, Andrew J. Mungall, Jacqueline E. Schein, Yussanne Ma, Nina Thiessen, Karen L. Mungall, Richard Corbett, Peter Eirew, Caralyn Reisle, Carolyn Ch'ng, Pinaki Bose, Martin Jones, Sreeja Leelakumari, Katayoon Kasaian, Erin Pleasance, Yaoqing Shen, Eric Y. Zhao
Purpose: Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric cancers. There is an urgent need to understand the clinical implicatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::038f8bfa7c888a7b5ba40167f7c2a543
https://doi.org/10.1158/1078-0432.c.6525044
https://doi.org/10.1158/1078-0432.c.6525044